Caricamento azienda
Just reported
Q3 2026 results
From Omnicell's results release of 29 ottobre 2026; its quarterly report has since been filed.
Revenue
Actual
307,9M USD
-0,9% y/y
-1,4% q/qGuided
304M USD
midpoint
Above guide+1,3%EPS, GAAP
Actual
0,24 USD
+100% y/y
-54% q/qGuided
—
No guide given
Operating income, GAAP
Actual
14,9M USD
+81% y/y
-54% q/qGuided
—
No guide given
Company outlook
Q4 2026
- Revenue295M USD – 301M USD-5,1% y/y First given
- EPS, adjusted0,41 USD – 0,49 USDFirst given
Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.
Keep exploring
The themes Omnicell is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.
Highest-graded in Health Information Services
Graded A or B and worth $2B or more: A first, then the largest.
VEEVVeeva Systems Inc.48,9B USDA+
BTSGBrightSpring Health Services, Inc.14,2B USDA
HNGEHinge Health, Inc.9,4B USDA+
HQYHealthequity, Inc.8,6B USDA+
DOCSDoximity, Inc.5,9B USDB+
Grade rose recently in Healthcare
Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.
DHRDanaher Corporation21 ott 2026CBGraded C, now B
MCKMckesson Corporation4 nov 2026BAGraded B, now A
CVSCVS Health Corp4 nov 2026BAGraded B, now A
EWEdwards Lifesciences Corporation4 nov 2026BAGraded B, now A
GEHCGE Healthcare Technologies Inc.28 ott 2026CAGraded C, now A
Costruito dai documenti depositati da Omnicell, Inc. presso la Securities and Exchange Commission (SEC), l’autorità di vigilanza statunitense. Le cifre sono quelle dichiarate, con lo storico per azione ricalcolato sulla base azionaria di oggi. Questo descrive un’azienda: non è consulenza finanziaria né una raccomandazione di acquisto o vendita.
